Your browser is no longer supported. Please, upgrade your browser.
Settings
PBYI Puma Biotechnology, Inc. daily Stock Chart
PBYI [NASD]
Puma Biotechnology, Inc.
Index- P/E- EPS (ttm)-8.29 Insider Own11.60% Shs Outstand36.56M Perf Week6.11%
Market Cap1.46B Forward P/E- EPS next Y-4.64 Insider Trans-0.49% Shs Float31.80M Perf Month1.78%
Income-276.00M PEG- EPS next Q-1.96 Inst Own96.80% Short Float25.37% Perf Quarter24.84%
Sales- P/S- EPS this Y-11.30% Inst Trans0.00% Short Ratio8.14 Perf Half Y-8.48%
Book/sh5.88 P/B6.79 EPS next Y44.20% ROA-144.70% Target Price68.67 Perf Year23.76%
Cash/sh6.28 P/C6.36 EPS next 5Y- ROE-186.20% 52W Range19.74 - 73.27 Perf YTD30.13%
Dividend- P/FCF- EPS past 5Y-44.40% ROI- 52W High-44.66% Beta0.46
Dividend %- Quick Ratio6.30 Sales past 5Y- Gross Margin- 52W Low105.42% ATR2.15
Employees160 Current Ratio6.30 Sales Q/Q- Oper. Margin- RSI (14)59.63 Volatility4.19% 5.99%
OptionableYes Debt/Eq0.00 EPS Q/Q-7.00% Profit Margin- Rel Volume0.85 Prev Close39.95
ShortableYes LT Debt/Eq0.00 EarningsMay 31 AMC Payout- Avg Volume990.89K Price40.55
Recom1.90 SMA2010.03% SMA506.50% SMA200-6.35% Volume764,814 Change1.50%
Mar-02-17Reiterated RBC Capital Mkts Sector Perform $48 → $17
Sep-22-16Reiterated Credit Suisse Outperform $54 → $111
Sep-21-16Upgrade Stifel Hold → Buy $61 → $88
Mar-29-16Downgrade RBC Capital Mkts Outperform → Sector Perform $103 → $36
Jan-21-16Initiated Credit Suisse Outperform
Dec-14-15Upgrade Citigroup Neutral → Buy
Sep-03-15Initiated Citigroup Neutral
Aug-27-15Initiated JP Morgan Overweight $122
Jan-23-15Initiated RBC Capital Mkts Outperform $282
Aug-19-14Resumed Stifel Hold
Jul-23-14Reiterated UBS Buy $125 → $325
Dec-19-13Reiterated UBS Buy $61 → $125
Dec-19-13Downgrade Stifel Buy → Hold
Jul-22-13Reiterated Stifel Buy $42 → $64
Jun-03-13Reiterated UBS Buy $35 → $49
Mar-25-13Reiterated Stifel Buy $32 → $42
Mar-20-13Reiterated UBS Buy $27 → $35
Apr-18-17 01:31PM  Shortened FDA Advisory Panel Is Bad Omen for Puma Bio's Controversial Breast Cancer Drug TheStreet.com -6.94%
Apr-17-17 08:03AM  Puma Biotechnology Announces FDA Advisory Committee to Review Neratinib for the Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer Business Wire +11.08%
Apr-04-17 01:05PM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting Business Wire
01:05PM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2017 AACR Annual Meeting
Apr-02-17 03:03PM  Puma Biotechnology Presents Interim Results of Phase Ib/II FB-10 Trial of PB272 in Combination with Trastuzumab Emtansine (T-DM1) in HER2-Positive Metastatic Breast Cancer at the 2017 AACR Annual Meeting Business Wire
11:03AM  Puma Biotechnology Presents Results from the Phase II SUMMIT Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Cancer at the 2017 AACR Annual Meeting Business Wire
10:30AM  Puma Biotechnology Launches Expanded Access Program for PB272 (Neratinib) for U.S. Patients with HER2-Positive Breast Cancer or HER2-Mutated Cancers Business Wire
Mar-24-17 05:00PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Changes in Registrant's Certifying Accountant, Financial Statements and
Mar-20-17 01:00PM  Finding Bullish and Bearish Market Reversals TheStreet.com
01:00PM  Finding Bullish and Bearish Market Reversals
Mar-09-17 07:00AM  7 Stocks Trending Up With Monster Volume TheStreet.com
07:00AM  7 Stocks Trending Up With Monster Volume
Mar-08-17 04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High Investor's Business Daily +13.20%
04:26PM  Puma Leads Massive Biotech Surge As Esperion Hits 15-Month High
Mar-07-17 01:04PM  PUMA BIOTECHNOLOGY, INC. Financials +5.79%
Mar-02-17 05:31PM  Kroger, Shake Shack and Puma dip; Monster Beverage gains Associated Press -13.80%
05:31PM  Kroger, Shake Shack and Puma dip; Monster Beverage gains
04:53PM  Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus Zacks
04:53PM  Puma (PBYI) Q4 Loss Wider than Expected, Neratinib in Focus
04:43PM  Why Puma Biotechnology Inc. Got Hammered Today at Motley Fool
04:20PM  Puma Biotechnology to Present at Cowens Health Care Conference Business Wire
12:05PM  Puma Plunges on Breast Cancer Drug Update at Investopedia
10:42AM  Top Biotech Stocks With FDA Decisions in 2017 at Motley Fool
09:14AM  Puma Biotech shares plummet 26% after Roche reports positive results for late-stage breast cancer drug at MarketWatch
06:36AM  Roche Shares Soar, Puma Bio Sinks on Perjeta Breast Cancer Study Win
Mar-01-17 06:08PM  Puma Biotech reports 4Q loss
06:02PM  Puma Biotechnology Announces Publication of Abstracts on Neratinib for the AACR Annual Meeting 2017 Business Wire
04:59PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
04:46PM  Puma Biotechnology Provides Update on Review of Marketing Authorisation Application for PB272 Business Wire
04:20PM  Puma Biotechnology Reports Fourth Quarter and Full Year 2016 Financial Results Business Wire
04:11PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 10-K, Annual Report
Feb-27-17 08:28AM  Puma Biotechnology (PBYI) Q4 Earnings: What's in the Cards?
Feb-14-17 04:15PM  Puma Biotechnology to Present at RBC Capital Markets Healthcare Conference Business Wire
Feb-08-17 04:15PM  Puma Biotechnology to Present at LEERINK Partners Global Healthcare Conference Business Wire +10.04%
Feb-03-17 09:19AM  Biotech Stock Mailbag: Do Investors Have an 'Aphinity' for Shorting Puma Into Trial Results?
Jan-09-17 06:07PM  Puma (PBYI) Expands Study Cohort for Lead Candidate PB272
04:55PM  Newman Ferrara LLP Announces Corporate Governance Investigation of Puma Biotechnology, Inc. - PBYI Business Wire
Jan-06-17 02:13PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
08:15AM  Puma Biotechnology Expands Cohort in Phase II SUMMIT Trial of PB272 in HER2 Mutation-Positive Cancer Patients Business Wire
Jan-03-17 04:15PM  Puma Biotechnology to Present at J.P. Morgan Healthcare Conference Business Wire
Dec-19-16 04:27PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or St
04:15PM  Puma Biotechnology to Move Stock Exchange Listing to Nasdaq Business Wire
Dec-08-16 12:38PM  Puma Cancer Drug Suffers 'Approvability Risk' On Extreme Side Effect -8.42%
08:46AM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events
08:35AM  Puma Biotechnology Presents Interim Results of Phase II CONTROL Trial of PB272 in Extended Adjuvant Treatment of HER2-Positive Early Stage Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
Dec-07-16 06:21PM  Puma Biotechnology Presents Results of Biomarker Analysis of Phase II Trial of PB272 in Neoadjuvant Treatment of HER2-Positive Locally Advanced Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
06:07PM  Puma Biotechnology Presents Interim Results of Phase II Trial of PB272 for ERBB2 (HER2) Mutant, HER2 Non-Amplified, Metastatic Breast Cancer at the 2016 San Antonio Breast Cancer Symposium Business Wire
07:00AM  Cascadian Therapeutics Enlarges Breast Cancer Pill Study to Meet FDA Registration Standards
Dec-06-16 06:44PM  CORRECTING and REPLACING Puma Biotechnology Initiates a Managed Access Program for PB272 (Neratinib) Outside the United States Business Wire
Nov-30-16 09:33AM  Why Did Puma Biotechnology Dilute Shareholders? at Motley Fool
Nov-28-16 02:11PM  Puma Biotechnology, Inc. :PBYI-US: Earnings Analysis: Q3, 2016 By the Numbers : November 28, 2016 -5.31%
Nov-22-16 08:12AM  Shareholder Dilution: What Investors Need to Know at Motley Fool
Nov-19-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Nov-15-16 03:57PM  SHAREHOLDER ALERT: Goldberg Law PC Announces an Investigation of Puma Biotechnology, Inc. and Advises Investors with Losses to Contact the Firm Business Wire +7.36%
03:11PM  Heres Why The Puma Biotechnology Inc (PBYI) Pullback Might Be A Buy-In Opportunity at Insider Monkey
03:10PM  SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Puma Biotechnology, Inc. (PBYI) PR Newswire
01:00PM  SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Puma Biotechnology, Inc. - PBYI PR Newswire
Nov-14-16 07:16PM  Puma Biotechnology Announces Presentations of Investigational Data at the San Antonio Breast Cancer Symposium (SABCS) Business Wire -20.44%
05:36PM  What Caused Puma Biotechnology's Shares to Tumble 20.5% Today at Motley Fool
04:37PM  Credit Suisse Says Gr3 Diarrhea Still A Concern For Puma Biotech, But Pullback Is Overdone
01:13PM  Puma Biotechnology falls more than 20% at CNBC
11:25AM  Puma Bio Falls on Escalating Concerns About Diarrhea Risk With Breast Cancer Drug
Nov-11-16 10:07PM  Puma Investigation Initiated By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. - PBYI PR Newswire
Nov-10-16 07:50AM  Puma (PBYI) Posts Wider Loss in Q3, Neratinib in Focus
Nov-09-16 05:29PM  Puma Biotech reports 3Q loss +16.25%
05:24PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and
04:15PM  Puma Biotechnology Reports Third Quarter 2016 Financial Results Business Wire
04:11PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 10-Q, Quarterly Report
Nov-03-16 06:24PM  Puma Biotechnology (PBYI) Q3 Earnings: What's in Store? -9.31%
Oct-31-16 04:15PM  Puma Biotechnology to Present at Credit Suisse Healthcare Conference Business Wire
11:38AM  Lifshitz & Miller Law Firm Announces Investigation of Electronics for Imaging, Inc., Ferrellgas Partners LP, Fusion Pharm, Inc., Humana Inc., KemPharm, Inc., National Beverage Corp., Puma Biotechnology, Inc., and TG Therapeutics, Inc. PR Newswire
Oct-28-16 10:07PM  PUMA INVESTIGATION INITIATED BY FORMER LOUISIANA ATTORNEY GENERAL: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. PBYI Business Wire
Oct-25-16 11:45AM  Puma Biotechnology Closes $172 Million Public Offering of Common Stock Business Wire
Oct-23-16 10:15AM  4 Companies That Destroyed Shareholders Last Week at 24/7 Wall St.
Oct-21-16 05:04PM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits
12:34PM  Puma Biotech, Which Had Weak Demand For A Secondary Offering, Is Also Part Of The SEC Tick Size Pilot Program
08:31AM  Puma Biotechnology Announces Underwriters Full Exercise of Option to Purchase Additional Shares Business Wire
Oct-20-16 08:40AM  Puma Bio's Desperate Money Grab Signals Breast Cancer Drug Trouble
04:43AM  Ups And Downs In Biotech This Week: PTC Therapeutics, Inc. (PTCT), Puma Biotechnology Inc (PBYI) and Nektar Therapeutics (NKTR) at Insider Monkey
Oct-19-16 11:18PM  Puma Biotechnology Prices Public Offering of Common Stock Business Wire -18.90%
03:43PM  Puma Biotech Gears Up for Secondary Offering
01:01PM  Why Puma Biotechnology Inc. Sold Lower Today at Motley Fool
09:07AM  Why Traders Are Watching Manhattan Associates, Meridian Bioscience, Puma Biotechnology, Tesla and More at Insider Monkey
Oct-18-16 05:53PM  Puma Biotechnology (PBYI) Stock Down in After-Hours Trading on Public Offering
04:36PM  Puma Biotech shares slide on secondary stock offering at MarketWatch
04:15PM  Puma Biotechnology Announces Proposed Public Offering of Common Stock Business Wire
Oct-17-16 06:04AM  PUMA BIOTECHNOLOGY, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhi
Oct-14-16 10:07PM  PUMA INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates Puma Biotechnology, Inc. PBYI Business Wire
Oct-12-16 02:52PM  Robbins Arroyo LLP: Puma Biotechnology, Inc. (PBYI) Investors Survive Defendants' Motion to Dismiss in Securities Class Action Business Wire
Oct-11-16 11:30AM  Puma Biotechnology, Inc. Shareholder Alert: Schubert Firm Investigates Company's Top Executives PR Newswire
Oct-10-16 10:32AM  Johnson & Weaver, LLP Initiates Investigations of Puma Biotechnology, Inc., Virtus Investment Partners, Inc., AAC Holdings, Inc. and Spectrum Pharmaceuticals, Inc.; Encourages Long-Term Investors to Contact the Firm Regarding Their Legal Ri PR Newswire
Oct-04-16 10:15AM  Lawsuit for Investors in shares of Puma Biotechnology Inc (NYSE:PBYI) against Directors announced by Shareholders Foundation GlobeNewswire
Sep-30-16 09:13AM  5 Top Performing Stocks of the Best ETF of Q3
09:10AM  SEC Issues Charges Over Biotech Insider Activity
07:00AM  Biotech Stock Mailbag: Dynavax, Puma, Ariad
Sep-29-16 04:05PM  SEC charges former Puma Biotech employee with insider trading Reuters
Sep-27-16 11:49AM  Momentum Carries Lululemon Lower, Pushes Biotech Names Higher at Forbes
Sep-25-16 10:45AM  6 Biotech and Biohealth Analyst Picks for 50% to 150% Upside at 24/7 Wall St.
10:20AM  Could Puma Biotech Double After This FDA Approval? at 24/7 Wall St.
Sep-22-16 04:31PM  Puma Races To Eight-Month High On Breast Cancer Drug Success
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to improve cancer care. Its drug candidates include PB272 (neratinib (oral)) for the treatment of early stage breast cancer, metastatic breast cancer, non-small cell lung cancer, HER2 mutation-positive solid tumors, and HER2-mutated non-amplified breast cancer; and PB272 (neratinib (intravenous)). The company also develops PB357, an orally administered agent that is an irreversible tyrosine kinase inhibitor that blocks signal transduction through the epidermal growth factor receptors, HER1, HER2, and HER4. It has a license agreement with Pfizer, Inc. for the development, manufacture, and commercialization of PB272 neratinib (oral), PB272 neratinib (intravenous), PB357, and certain related compounds. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
CHARNAS ROBERTFeb 01Sale31.833,00895,75526,453Feb 02 05:43 PM
Lo StevenChief Commercial OfficerJan 20Sale33.242,29076,10829,210Jan 24 05:56 PM
EYLER CHARLES RSEE REMARKSJan 20Sale33.2482027,2539,680Jan 24 05:53 PM
CHARNAS ROBERTJan 20Sale33.242,29376,20829,407Jan 24 05:52 PM
BRYCE RICHARD PAULSR VP, CLINICAL RESEARCH & DEVJan 20Sale33.242,29376,20829,237Jan 24 05:51 PM
AUERBACH ALAN HPRESIDENT AND CEOJan 20Sale33.2410,202339,0644,179,798Jan 24 05:49 PM